ARTICLESAlteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion
References (17)
- et al.
Acute pulmonary embolism treated with tissue plasminogen activator
Lancet
(1986) - et al.
Early reversal of right ventricular dysfunction in patients with acute pulmonary embolism after treatment with intravenous tissue plasminogen activator
JACC
(1987) - et al.
Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism
Lancet
(1988) - et al.
Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomised controlled multicenter trial
JACC
(1992) - et al.
Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: a European multicenter double-blind trial
JACC
(1992) - et al.
PAIMS 2: Alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism: Plasminogen Activator Italian Multicenter Study 2
JACC
(1992) Pulmonary embolism thrombolysis: a clarion call for international collaboration
JACC
(1992)- et al.
Pulmonary perfusion after rt-PA therapy for acute embolism: early improvement assessed with segmental perfusion scanning
Radiology
(1988)
There are more references available in the full text version of this article.
Cited by (787)
Safety and efficacy of clot-dissolving therapies for submassive pulmonary embolism: A network meta-analysis of randomized controlled trials
2024, Cardiovascular Revascularization MedicinePrOgnosis in Pulmonary Embolism (PoPE): 30-Day mortality risk score based on five admission parameters
2024, Revista Portuguesa de CardiologiaThe prognostic value of time from symptom onset to thrombolysis in patients with pulmonary embolism
2022, International Journal of Cardiology
Copyright © 1993 Published by Elsevier Ltd.